FAP and head and neck cancer: Similarly a ligand for a different co-stimulatory receptor CD40 was linked to a bispecific FAP antibody to ensure activation of CD40 was only induced around FAP-expressing cells in an experimental model of murine head and neck cancer that synergised with radiotherapy causing tumour regression and long term survival (94) (Figure 2C).